TY - JOUR
T1 - Gene expression profiling in kidney cancer
T2 - Combining differential expression and chromosomal and pathway analyses
AU - Furge, Kyle A.
AU - Kort, Eric J.
AU - Yang, Ximing J.
AU - Stadler, Walter M.
AU - Kim, Hyung
AU - Teh, Bin Tean
PY - 2006/12
Y1 - 2006/12
N2 - The high-throughput gene expression profiling by microarray analysis has enabled researchers to compare the relative expression levels of thousands of genes in diseases, including cancer. By identifying how these genes cluster in different carcinomas, these profiling techniques can improve the accuracy of classifying subtypes of tumors and their prognoses and could help determine which therapy is appropriate for each patient with cancer. These efforts aim to provide more effective personalized medicine. To reach this goal, the analysis of microarray data has also evolved and become more sophisticated and complex. Herein, using kidney cancer as an example, we demonstrate the use of microarray data for different bases of analysis, ie, direct differential expression, deduced chromosomal alteration, and pathways signature. We believe combining these will enhance the value of microarray studies and will better serve the goals we try to achieve using these data.
AB - The high-throughput gene expression profiling by microarray analysis has enabled researchers to compare the relative expression levels of thousands of genes in diseases, including cancer. By identifying how these genes cluster in different carcinomas, these profiling techniques can improve the accuracy of classifying subtypes of tumors and their prognoses and could help determine which therapy is appropriate for each patient with cancer. These efforts aim to provide more effective personalized medicine. To reach this goal, the analysis of microarray data has also evolved and become more sophisticated and complex. Herein, using kidney cancer as an example, we demonstrate the use of microarray data for different bases of analysis, ie, direct differential expression, deduced chromosomal alteration, and pathways signature. We believe combining these will enhance the value of microarray studies and will better serve the goals we try to achieve using these data.
KW - Clinical implications
KW - Diagnosis
KW - Microarray analysis
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=33846704043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846704043&partnerID=8YFLogxK
U2 - 10.3816/CGC.2006.n.041
DO - 10.3816/CGC.2006.n.041
M3 - Article
C2 - 17239277
AN - SCOPUS:33846704043
SN - 1558-7673
VL - 5
SP - 227
EP - 231
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 3
ER -